Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 May;23(3):499-509.
doi: 10.1007/s12282-015-0593-z. Epub 2015 Feb 6.

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Eiichi Shiba  1 , Hiroko Yamashita  2   3 , Junichi Kurebayashi  4 , Shinzaburo Noguchi  5 , Hirotaka Iwase  6 , Yasuo Ohashi  7 , Kiyofumi Sasai  8 , Tsukasa Fujimoto  8
Affiliations
Randomized Controlled Trial

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Eiichi Shiba et al. Breast Cancer. 2016 May.

Abstract

Background: Luteinizing hormone-releasing hormone (LH-RH) agonists provide effective adjuvant treatment for premenopausal women with endocrine-responsive breast cancer. Here, we investigated appropriate treatment durations of an LH-RH agonist, leuprorelin.

Methods: We conducted an open-label, randomized controlled pilot study to evaluate the safety and efficacy of leuprorelin subcutaneously administered every-3-months for 2 versus 3 or more, up to 5 years, together with daily tamoxifen for 5 years in premenopausal endocrine-responsive breast cancer patients. Primary endpoints were disease-free survival (DFS) and safety.

Results: Eligible patients (N = 222) were randomly assigned to receive leuprorelin for either 2 years (N = 112) or 3 or more years (N = 110) with tamoxifen for 5 years after surgery. Leuprorelin treatment for 3 or more years provided no significant difference in DFS rate over 2 years: 94.1 versus 91.8 % at 144 weeks (3 years) after the second year (week 96) and 90.8 versus 90.4 % at the fifth year (week 240). The overall survival rate was 100 % for both groups during the third through fifth year study period. There were no significant differences in the incidence of adverse events (AEs) between the 2 groups: most AEs were rated grade 1 or 2.

Conclusions: Adjuvant leuprorelin treatment for 3 or more years with tamoxifen showed a survival benefit and safety profile similar to that for 2 years in premenopausal endocrine-responsive breast cancer patients. No new safety signal was identified for long-term leuprorelin treatment. Longer follow-up observation is needed to determine the optimal duration of leuprorelin treatment.

Keywords: Adjuvant endocrine therapy; Disease-free survival (DFS); Leuprorelin acetate; Premenopausal endocrine-responsive breast cancer; Safety.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient disposition, N number of patients evaluated
Fig. 2
Fig. 2
Kaplan–Meier analysis of disease-free survival for patients a during the overall 5-year study period and b during the third through fifth year study period. HR hazard ratio, CI confidence interval
Fig. 3
Fig. 3
Time course of mean changes from baseline in serum estradiol levels throughout the 5-year study period. Data indicate the mean + SD. SD standard deviation, E 2 estradiol
Fig. 4
Fig. 4
Time course of the mean change rates from baseline in bone mineral density in the lumbar spine in patients a without or b with concomitant anti-osteoporosis treatment throughout the 5-year study period. Data indicate the mean + SD. SD standard deviation
See this image and copyright information in PMC

References

    1. Goldhirsch A,Glick JH, Gelber D, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the treatment of primary breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001; 19:3817–3827. - PubMed
    1. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20:4628–4635. doi: 10.1200/JCO.2002.05.042. - DOI - PubMed
    1. International Breast Cancer Study Group (IBCSG) Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node–negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003;95:1833–1846. doi: 10.1093/jnci/djg119. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451–1467. doi: 10.1016/S0140-6736(97)11423-4. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources